Strategy and objectives
Immunovia’s strategy is to use our IMMray™ platform and approach to develop and establish more accurate and reliable tools for early detection of cancer and autoimmune diseases. This leads to more effective treatment, and to clinically useful and economically sustainable tools that improve healthcare globally.
The focus is on diseases where early detection and monitoring create significant clinical benefit for patients and healthcare, and where existing solutions today are either missing or insufficient.
The first product to be launched is IMMray™ PanCan-d, a test for early diagnosis of pancreatic cancer in high-risk groups with the potential to significantly increase survival rates.
Immunovia’s goal is to be the first company to launch a blood test for early detection of pancreatic cancer. Furthermore, the aim is to establish it as the standard test for specialists in pancreatic cancer and diabetes worldwide for detecting pancreatic cancer in high-risk groups at an earlier stage than is possible today.
The long-term goal is a market penetration of 30% in Europe and the US.